{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:35:39Z","timestamp":1769250939968,"version":"3.49.0"},"reference-count":36,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>This study aimed to assess the efficacy of a novel prophylactic scheme of fosfomycin trometamol in patients undergoing elective HoLEP (holmium laser enucleation of the prostate) or TURP (transurethral resection of the prostate) procedures for treating benign prostatic hyperplasia. Patients affected by benign prostatic hyperplasia and undergoing elective HoLEP or TURP procedures during the period February 2022\u2013June 2023 were prospectively enrolled. Two 3 g oral fosfomycin trometamol doses 12 h apart were administered at 8.00 p.m. on day \u22121 (i.e., the day before HoLEP or TURP procedure) and at 8.00 a.m. on day 0 (i.e., the day of the surgical procedure). The following outcomes were assessed: prevalence of fever occurring in the first 48 h after surgical procedure; prevalence of urological complications occurring after the surgical procedure; prevalence of proven urinary tract infections (UTIs) and\/or bloodstream infections (BSIs) at 14 days post-procedure; and prevalence of emergency department admission for UTI-related sepsis at 14 days post-procedure. Univariate analysis comparing patients with and without proven UTI, BSI, or emergency department admission at 14 days post-procedure was carried out. Overall, 96 patients (median age 70 years) undergoing HoLEP (82.3%) or TURP (17.7%) were prospectively included. Median (IQR) time of surgical procedure after the morning fosfomycin dose was 226.5 min (range 88.5\u2013393.75 min). Fever in the post-surgical 48 h occurred in 3\/96 patients (3.1%). Prevalence of proven UTI at 14 days was as low as 1.0% (1\/96), whereas no patient had proven BSI or UTI-related sepsis requiring emergency department admission at 14 days. Our findings support the contention that a prophylactic scheme based on two doses of fosfomycin trometamol 12 h apart before surgical intervention may represent a valuable strategy for preventing infectious complications in urologic patients undergoing HoLEP or TURP. Larger definitive confirmatory studies are warranted.<\/jats:p>","DOI":"10.3390\/antibiotics13050424","type":"journal-article","created":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T15:05:01Z","timestamp":1715007901000},"page":"424","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study"],"prefix":"10.3390","volume":"13","author":[{"given":"Pasquale Maria","family":"Berrino","sequence":"first","affiliation":[{"name":"Division of Urology, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-3779","authenticated-orcid":false,"given":"Milo","family":"Gatti","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"},{"name":"Clinical Pharmacology Unit, Department for integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Rotaru","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Bianchi","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9059-3991","authenticated-orcid":false,"given":"Fabio","family":"Tumietto","sequence":"additional","affiliation":[{"name":"Antimicrobical Stewardship Unit, Department for integrated Infectious Risk Management, Azienda USL of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Sora","sequence":"additional","affiliation":[{"name":"Antimicrobical Stewardship Unit, Department for integrated Infectious Risk Management, Azienda USL of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Schiavina","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenio","family":"Brunocilla","sequence":"additional","affiliation":[{"name":"Division of Urology, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"},{"name":"Infectious Disease Unit, Department for Integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-7167","authenticated-orcid":false,"given":"Federico","family":"Pea","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy"},{"name":"Clinical Pharmacology Unit, Department for integrated Infectious Risk Management, IRCCS Azienda Ospedaliero-Universitaria of Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/0970-1591.126900","article-title":"Epidemiology and Etiology of Benign Prostatic Hyperplasia and Bladder Outlet Obstruction","volume":"30","author":"Patel","year":"2014","journal-title":"Indian J. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.eururo.2005.12.042","article-title":"Complications of Transurethral Resection of the Prostate (TURP)\u2014Incidence, Management, and Prevention","volume":"50","author":"Rassweiler","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_3","first-page":"13","article-title":"Holmium Laser Enucleation of the Prostate (HoLEP): A Review and Update","volume":"26","author":"Das","year":"2019","journal-title":"Can. J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1179\/1120009X14Z.000000000233","article-title":"Aetiology and Antibiotic Resistance Issues Regarding Urological Procedures","volume":"26","author":"Concia","year":"2014","journal-title":"J. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijantimicag.2011.09.008","article-title":"Antibiotic Prophylaxis in Urological Surgery, a European Viewpoint","volume":"38","author":"Grabe","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.juro.2008.01.068","article-title":"Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy Panel Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis","volume":"179","author":"Wolf","year":"2008","journal-title":"J. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.12968\/hmed.2006.67.2.20472","article-title":"Multi-Resistant Escherichia Coli Sepsis Following Transrectal Ultrasound-Guided Prostate Biopsy","volume":"67","author":"Davidson","year":"2006","journal-title":"Br. J. Hosp. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/cid\/cit193","article-title":"Infectious Complications Following Transrectal Ultrasound-Guided Prostate Biopsy: New Challenges in the Era of Multidrug-Resistant Escherichia Coli","volume":"57","author":"Williamson","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2016.02.001","article-title":"Susceptibility of Contemporary Isolates to Fosfomycin: A Systematic Review of the Literature","volume":"47","author":"Vardakas","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","article-title":"Fosfomycin Tromethamine: A Review of Its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Efficacy as a Single-Dose Oral Treatment for Acute Uncomplicated Lower Urinary Tract Infections","volume":"53","author":"Patel","year":"1997","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dijkmans, A.C., Zacar\u00edas, N.V.O., Burggraaf, J., Mouton, J.W., Wilms, E.B., van Nieuwkoop, C., Touw, D.J., Stevens, J., and Kamerling, I.M.C. (2017). Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics, 6.","DOI":"10.3390\/antibiotics6040024"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","article-title":"Fosfomycin: An Old\u2014New Antibiotic","volume":"18","author":"Raz","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Di Stefano, A.F.D., Radicioni, M.M., Morano, F., Gentili, A., Mallat, E., Cuomo, D., Mazzarella, T., and Di Fonzo, V. (2022). Fosfomycin Pharmacokinetic Profile in Plasma and Urine and Quantitative Estimation in Prostate and Seminal Vesicles after One and Two Consecutive Doses of Oral Fosfomycin Trometamol in Healthy Male Volunteers. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111458"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000355103","article-title":"Fosfomycin Trometamol (3000 Mg) in Perioperative Antibiotic Prophylaxis of Healthcare-Associated Infections after Endourological Interventions: A Narrative Review","volume":"92","author":"Wagenlehner","year":"2014","journal-title":"Urol. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"106983","DOI":"10.1016\/j.ijantimicag.2023.106983","article-title":"Rediscovering the Value of Fosfomycin Trometamol in the Era of Antimicrobial Resistance: A Systematic Review and Expert Opinion","volume":"62","author":"Cai","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.tmaid.2017.01.003","article-title":"Fluoroquinolone Antibiotic Users Select Fluoroquinolone-Resistant ESBL-Producing Enterobacteriaceae (ESBL-PE)\u2014Data of a Prospective Traveller Study","volume":"16","author":"Kantele","year":"2017","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1345\/aph.1M696","article-title":"The Relationship between Inpatient Fluoroquinolone Use and Clostridium Difficile-Associated Diarrhea","volume":"44","author":"Novell","year":"2010","journal-title":"Ann. Pharmacother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/jac\/dkv067","article-title":"Optimal Timing of Oral Fosfomycin Administration for Pre-Prostate Biopsy Prophylaxis","volume":"70","author":"Rhodes","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4081\/aiua.2020.2.82","article-title":"Holmium Laser Prostatectomy in a Tertiary Italian Center: A Prospective Cost Analysis in Comparison with Bipolar TURP and Open Prostatectomy","volume":"92","author":"Schiavina","year":"2020","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.euf.2021.04.004","article-title":"Short Time Delay Between Previous Prostate Biopsy for Prostate Cancer Assessment and Holmium Laser Enucleation of the Prostate Correlates with Worse Perioperative Outcomes","volume":"8","author":"Piazza","year":"2022","journal-title":"Eur. Urol. Focus"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/13645700601159410","article-title":"Bipolar Transurethral Resection of the Prostate\u2014Technical Modifications and Early Clinical Experience","volume":"16","author":"Rassweiler","year":"2007","journal-title":"Minim. Invasive Ther. Allied Technol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/pros.24259","article-title":"Long-term Outcomes of Holmium Laser Enucleation of Prostate and Predictive Model for Symptom Recurrence","volume":"82","author":"Droghetti","year":"2022","journal-title":"Prostate"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/end.1998.12.457","article-title":"Holmium Laser Enucleation of the Prostate (HoLEP) Combined with Transurethral Tissue Morcellation: An Update on the Early Clinical Experience","volume":"12","author":"Gilling","year":"1998","journal-title":"J. Endourol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00134-022-06968-8","article-title":"Multidrug-Resistant Bacteria in the Grey Shades of Immunosuppression","volume":"49","author":"Russell","year":"2023","journal-title":"Intensive Care Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/phar.2231","article-title":"Augmented Renal Clearance","volume":"39","author":"Cook","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN Surveillance Definition of Health Care-Associated Infection and Criteria for Specific Types of Infections in the Acute Care Setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am. J. Infect. Control"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Shallcross, L.J., Rockenschaub, P., McNulty, D., Freemantle, N., Hayward, A., and Gill, M.J. (2020). Diagnostic Uncertainty and Urinary Tract Infection in the Emergency Department: A Cohort Study from a UK Hospital. BMC Emerg. Med., 20.","DOI":"10.1186\/s12873-020-00333-y"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1007\/BF01643437","article-title":"Prophylactic Chemotherapy with Fosfomycin Trometamol versus Placebo during Transurethral Prostatic Resection","volume":"18","author":"Baert","year":"1990","journal-title":"Infection"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000472877","article-title":"Prophylactic Chemotherapy withFosfomycin Trometamol Salt during Transurethral Prostatic Surgery: A Controlled Multicenter Clinical Trial","volume":"13","author":"Periti","year":"1987","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1007\/BF01643436","article-title":"Prophylactic Chemotherapy with Fosfomycin Trometamol during Transurethral Surgery and Urological Man\u0153uvres. Results of a Multicentre Study","volume":"18","author":"Ferrone","year":"1990","journal-title":"Infection"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S321","DOI":"10.1007\/BF01710024","article-title":"Oral Prophylaxis with Fosfomycin Trometamol in Transurethral Prostatectomy and Urological Maneuvers: Literature Review and Personal Experience","volume":"20","author":"Selvaggi","year":"1992","journal-title":"Infection"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00345-016-1867-6","article-title":"Antimicrobial Prophylaxis for Transrectal Ultrasound-Guided Prostate Biopsy: Fosfomycin Trometamol, an Attractive Alternative","volume":"35","author":"Cai","year":"2017","journal-title":"World J. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5152\/tud.2023.23030","article-title":"The Efficacy of Fosfomycin as Antibiotic Prophylaxis for Transrectal Prostate Biopsy and Impact on Lower Urinary Tract Symptom After Biopsy: A Prospective Study","volume":"49","author":"Cardoso","year":"2023","journal-title":"Urol. Res. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4111\/icu.20220413","article-title":"Effectiveness of Fosfomycin-Based Antimicrobial Prophylaxis for Transrectal Ultrasound-Guided Prostate Biopsy: A Korean Multicenter Study","volume":"64","author":"Lim","year":"2023","journal-title":"Investig. Clin. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1179\/1120009X14Z.000000000234","article-title":"Pharmacological Aspects of the Antibiotics Used for Urological Diagnostic Procedures","volume":"26","author":"Mazzei","year":"2014","journal-title":"J. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/cid\/cit704","article-title":"Is Fosfomycin a Potential Treatment Alternative for Multidrug-Resistant Gram-Negative Prostatitis?","volume":"58","author":"Gardiner","year":"2014","journal-title":"Clin. Infect. Dis."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/5\/424\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:40:08Z","timestamp":1760107208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/5\/424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,6]]},"references-count":36,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["antibiotics13050424"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13050424","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,6]]}}}